With use of 27.B1 and 27.F7 human monoclonal antibody specific to GIPC-1 protein, Yavelsky et al. [53] demonstrated, respectively, a positive immunnohistochemical staining for GIPC-1 in 7/13 (54%) and 8/15 (53%) of ovarian serous carcinomas, 4/11 (36%) and 0/11 (0%) of ovarian borderline serous tumors, 2/15 (14%) and 3/15 (21%) of ovarian serous cystadenomas, and 0/8 (0%) and 0/8 (0%) of normal ovarian tissues. The gene discussed is GIPC1; the disease is borderline ovarian serous tumor.